154 related articles for article (PubMed ID: 31245553)
1. A new method to address unmeasured confounding of mortality in observational studies.
Tannen R; Yu M
Learn Health Syst; 2017 Jan; 1(1):e10016. PubMed ID: 31245553
[TBL] [Abstract][Full Text] [Related]
2. Prior event rate ratio adjustment: numerical studies of a statistical method to address unrecognized confounding in observational studies.
Yu M; Xie D; Wang X; Weiner MG; Tannen RL
Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():60-8. PubMed ID: 22552981
[TBL] [Abstract][Full Text] [Related]
3. Advantages of large medical record database for outcomes research: Insights into post-menopausal hormone therapy.
Tannen RL; Barnhart KT; Rubin JC
Learn Health Syst; 2019 Jul; 3(3):e10193. PubMed ID: 31317074
[TBL] [Abstract][Full Text] [Related]
4. Replicated studies of two randomized trials of angiotensin-converting enzyme inhibitors: further empiric validation of the 'prior event rate ratio' to adjust for unmeasured confounding by indication.
Tannen RL; Weiner MG; Xie D
Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):671-85. PubMed ID: 18327852
[TBL] [Abstract][Full Text] [Related]
5. Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study.
Uddin MJ; Groenwold RH; van Staa TP; de Boer A; Belitser SV; Hoes AW; Roes KC; Klungel OH
Pharmacoepidemiol Drug Saf; 2015 May; 24(5):468-77. PubMed ID: 25410590
[TBL] [Abstract][Full Text] [Related]
6. Prior event rate ratio adjustment for hidden confounding in observational studies of treatment effectiveness: a pairwise Cox likelihood approach.
Lin NX; Henley WE
Stat Med; 2016 Dec; 35(28):5149-5169. PubMed ID: 27477530
[TBL] [Abstract][Full Text] [Related]
7. Assessing the prior event rate ratio method via probabilistic bias analysis on a Bayesian network.
Thommes EW; Mahmud SM; Young-Xu Y; Snider JT; van Aalst R; Lee JKH; Halchenko Y; Russo E; Chit A
Stat Med; 2020 Feb; 39(5):639-659. PubMed ID: 31788843
[TBL] [Abstract][Full Text] [Related]
8. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings.
Tannen RL; Weiner MG; Xie D
BMJ; 2009 Jan; 338():b81. PubMed ID: 19174434
[TBL] [Abstract][Full Text] [Related]
9. Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding.
Weiner MG; Xie D; Tannen RL
Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):661-70. PubMed ID: 18327857
[TBL] [Abstract][Full Text] [Related]
10. A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone.
Tannen R; Xie D; Wang X; Yu M; Weiner MG
Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):86-97. PubMed ID: 23070833
[TBL] [Abstract][Full Text] [Related]
11. Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study.
Rodgers LR; Dennis JM; Shields BM; Mounce L; Fisher I; Hattersley AT; Henley WE;
J Clin Epidemiol; 2020 Jun; 122():78-86. PubMed ID: 32194148
[TBL] [Abstract][Full Text] [Related]
12. [Confounder adjustment in observational comparative effectiveness researches: (2) statistical adjustment approaches for unmeasured confounders].
Huang LL; Wei YY; Chen F
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1450-1455. PubMed ID: 31838820
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. How unmeasured confounding in a competing risks setting can affect treatment effect estimates in observational studies.
Barrowman MA; Peek N; Lambie M; Martin GP; Sperrin M
BMC Med Res Methodol; 2019 Jul; 19(1):166. PubMed ID: 31366331
[TBL] [Abstract][Full Text] [Related]
15. Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study.
Ren J; Cislo P; Cappelleri JC; Hlavacek P; DiBonaventura M
BMC Med Res Methodol; 2023 Jan; 23(1):18. PubMed ID: 36647031
[TBL] [Abstract][Full Text] [Related]
16. Methods to control for unmeasured confounding in pharmacoepidemiology: an overview.
Uddin MJ; Groenwold RH; Ali MS; de Boer A; Roes KC; Chowdhury MA; Klungel OH
Int J Clin Pharm; 2016 Jun; 38(3):714-23. PubMed ID: 27091131
[TBL] [Abstract][Full Text] [Related]
17. Use of Bisphosphonates and the Risk of Skin Ulcer: A National Cohort Study Using Data from the French Health Care Claims Database.
Jambon-Barbara C; Bernardeau C; Bezin J; Roustit M; Blaise S; Cracowski JL; Khouri C
Drug Saf; 2023 Sep; 46(9):905-916. PubMed ID: 37531074
[TBL] [Abstract][Full Text] [Related]
18. Adjusting for unmeasured confounding in nonrandomized longitudinal studies: a methodological review.
Streeter AJ; Lin NX; Crathorne L; Haasova M; Hyde C; Melzer D; Henley WE
J Clin Epidemiol; 2017 Jul; 87():23-34. PubMed ID: 28460857
[TBL] [Abstract][Full Text] [Related]
19. The missing cause approach to unmeasured confounding in pharmacoepidemiology.
Abrahamowicz M; Bjerre LM; Beauchamp ME; LeLorier J; Burne R
Stat Med; 2016 Mar; 35(7):1001-16. PubMed ID: 26932124
[TBL] [Abstract][Full Text] [Related]
20. An E-value analysis of potential unmeasured or residual confounding in systematic reviews of post-tuberculosis mortality, respiratory disease, and cardiovascular disease.
Basham CA; Karim ME
Ann Epidemiol; 2022 Apr; 68():24-31. PubMed ID: 34973421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
